Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...

So, which respiratory virus invaded your cells? Several types of viruses could be the culprit: respiratory syncytial virus ...

There may be an increase in vaccine hesitancy but it isn't too late for those who would still want them, one doctor says.

Respiratory syncytial virus, or RSV, is a common virus that infects the nose, throat and lungs, according to the U.S. Centers ...

The RSVPreF vaccine is safe and demonstrates immunobridging to efficacy among adults aged 18 to 59 who are at high risk for ...

RSVpreF vaccination is effective against RSV-related lower respiratory tract disease among adults aged 60 years or older.

China pilots monitoring system for pneumonia of unknown origin amid rising respiratory infections, including human ...